Publications

A genome-wide associationmeta-analysis of all-cause and vascular dementia.

2024

Fongang B et al.

Alzheimer´s & Dementia 2024; doi: 10.1002/alz.14115. Online ahead of print.

An insertion within the SIRPβ1 gen shows a dual effect over Alzheimer’s disease cognitive decline altering the microglial response.

2024

García-Alberca JM, de Rojas I, Sánchez-Mejías E et al.

Journal of Alzheimer´s Disease 2023; 98: 601-618

Effect of Nordic Sensi® Chair on Behavioral and Psychological Symptoms of Dementia in Nursing Homes Residents: A Randomized Controlled Trial.

2023

García-Alberca JM, De la Rosa MD, Solo de Zaldívar P et al.

Journal of Alzheimer´s Disease 96 2023 1609–1622

Antidepressants in patients with neurological disorders.

2023

García-Alberca JM.

Kranion. 2023; 18:108-15

Genetic Associations Between Modifiable Risk Factors and Alzheimer Disease.

2023

Luo J, Thomassen JQ, Bellenguez C et al.

JAMA Netw Open. 2023 May 1;6(5):e2313734

Multi-ancestry HLA analysis in Alzheimer’s and Parkinson’s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04.

2023

GMignot et al. 120(36):e2302720120

The Proceedings of the National Academy of Sciences (PNAS)

Effects of antidepressant treatment on cognition in patients with Alzheimer’s disease.

2023

Garcia-Alberca JM,.

Kranion 2023; 18:27-33

An intragenic duplication within SIRPβ1 shows a dual effect over Alzheimer’s disease cognitive decline altering the microglial response.

2022

Garcia-Alberca JM, de Rojas I, Sanchez-Mejias E et al.

medRxiv 2022, https://doi.org/10.1101/2022.11.19.22282342

Rare missense variant (R251G) on APOE counterbalances the Alzheimer’s disease risk associated with APOE‐ε4.

2022

Guen YL, Belloy ME, Grenier‐Boley B et al.

Alzheimer’s & Dementia 18, e060114 2022

Identification of a sex-specific genetic signature in dementia with Lewy bodies: a meta-analysis of genome-wide association studies.

2022

Gibbons E, Rongve A, de Rojas I et al.

MedRxiv 2022

Combined treatment with Ginkgo biloba extract EGb 761 plus acetylcholinesterase inhibitors improved cognitive function and neuropsychiatric symptoms in patients with mild cognitive impairment.

2022

García-Alberca JM, Gris E, Mendoza S.

Alzheimers Dement (N Y) 2022; Aug 2;8(1):e12338.

Effects of tianeptine treatment on depression and cognitive function in patients with Alzheimer’s disease: a 12-month retrospective observational study.

2022

García-Alberca JM, Gris E, De la Guía P, Silvia Mendoza S.

Journal of Alzheimer´s Disease 2022; 88: 707–720.

Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease.

2022

Le Guen Y, Belloy ME, Grenier-Boley B et al.

JAMA Neurol May 31, 2022. doi:10.1001/jamaneurol.2022.1166.

New insights into the genetic etiology of Alzheimer’s disease and related dementias.

2022

Bellenguez C, Küçükali F, Jansen IE, et al.

Nature Genetics 2022 Apr 4. doi: 10.1038/s41588-022-01024-z.

Benefits of Treatment with Ginkgo Biloba Extract EGb 761 Alone or Combined with Acetylcholinesterase Inhibitors in Vascular Dementia.

2022

García-Alberca JM, Mendoza S, Gris E.

Clinical Drug Investigation 2022, doi: 10.1007/s40261-022-01136-8.

SARS-CoV-2 Infection in People with Dementia

Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study.

2021

de Rojas I , Isabel Hernández I Laura Montreal L. Quintela I, Calero M et al.

Journal of Personalized Medicine 2021; 11: 1318. doi.org/10.3390/jpm11121318.

gerald

The Genetic Research in Alzheimer Disease (GERALD) Initiative Finds rs9320913 as a Neural eQTL of lincRNA AL589740.1.

2021

Lopez-Gutierrez L, García-Alberca J, Mendoza S et al.

International Journal of Alzheimer´s Disease 2021; doi.org/10.1155/2021/3064224.

seis nuevas variantes genéticas3

Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores.

2021

de Rojas I, Moreno-Grau S, Tesi N et al.

Nature Communications 2021 Jun 7;12(1):3417. doi: 10.1038/s41467-021-22491-8.

A polygenic risk score for mosaic loss of chromosome Y susceptibility is associated with higher risk of MCI of AD conversión.

2021

García-González P, de Rojas I, Hernandez I et al.

Alzheimer´s Dementia 2021; DOI:10.1002/alz.053745.

homozigosidad-pub

Long runs of homozygosity are associated with Alzheimer’s disease.

2021

Moreno-Grau S, Maria Victoria Fernández MV, de Rojas I et al.

Translational Psychiatry 2021; Feb 24; 11(1):142. doi: 10.1038/s41398-020-01145-1

medrlarge

Large meta-analysis of genome-wide association studies expands knowledge of the genetic etiology of Alzheimer disease and highlights potential translational opportunities.

2020

Bellenguez C, Küçükali F, Jansen I, Andrade V, Moreno-Grau S et al.

medRxiv 2020; preprint doi: https://doi.org/10.1101/2020.10.01.20200659.

cardiocore_50

Factores de riesgo cardiovascular y deterioro cognitivo tras cirugía de revascularización coronaria sin circulación extracorpórea

2015

Pérez-Belmonte LM, San Román-Terán CM, Such M, Barbancho MA, Pérez-Díaz JM, Osuna-Sánchez J. García-Alberca JM, Lara JP

Cardiocore 2015 July DOI: 10.1016 / j.carcor.2015.06.005.

bior2020

Autosomal Recessive Alzheimer’s disease (arAD): homozygosity mapping of genomic regions containing arAD loci.

2020

Moreno-Grau S, Fernández MV, de Rojas I, Hernández I, Farias F et al.

bioRxiv preprint 2020; doi: https://doi.org/10.1101/2020.02.10.941393.

White matter lesions pub

White matter lesions and temporal atrophy are associated with cognitive and neuropsychiatric symptoms in patients with hypertension and Alzheimer´s disease.

2020

García‐Alberca JM, Mendoza S, Gris E, Royo JL, Cruz-Gamero JM, García-Casares N.

International Journal of Geriatric Psychiatry 2020; Doi.org/10.1002/gps.5366

medcommon

Common variants in Alzheimer’s disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores.

2019

de Rojas I, Moreno-Grau S, Tesi N, Grenier-Boley B et al.

medRxiv preprint 2019; doi: http://dx.doi.org/10.1101/19012021.

graceproject

Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer’s disease and three causality networks: The GR@ACE project.

2019

Moreno-Grau S, de Rojas I, Hernández I, Quintela I, Montrreal L, Alegret M et al.

Alzheimer´s and Dementia 2019; 15: 1333-1347

Cognitive–behavioural treatment for depression in Alzheimer’s disease patients: a case study

Medial temporal lobe atrophy is independently associated with behavioural and psychological symptoms in Alzheimer’s disease.

2018

García-Alberca JM, Florido M, Cáceres M, Sánchez-Toro A, Lara JP, García-Casares N

Psychogeriatrics 2018;19:46-54.

Cognitive-behavioral treatment for depressed patients with Alzheimer´s disease. An open trial.

Cognitive-behavioral treatment for depressed patients with Alzheimer´s disease. An open trial.

2017

García-Alberca JM

Archives of Gerontology and Geriatrics 2017; 71:1-8.

American_Journal_Alzheimer_32

A Path Analysis of Dependence and Quality of Life in Alzheimer’s Disease.

2017

Garre-Olmo J, Vilalta-Franch J, Calvó-Perxas L, López-Pousa S; CoDep-AD Study Group

American Journal of Alzheimer´s Disease and Other Dementias 2017; 32(2):108-115.

Efectos psicológicos y conductuales del Alzheimer

Efectos psicológicos y conductuales del Alzheimer

2016

García-Alberca JM

Mente y Cerebro 2016; 79: 50-56.

Terapias no farmacológicas en el alzhéimer

Terapias no farmacológicas del Alzheimer

2016

García-Alberca JM

Mente y Cerebro 2016; 81: 80-87.

neurologia_30

Cognitive intervention therapy as treatment for behaviour disorders in Alzheimer disease: Evidence on efficacy and neurobiological correlations

2015

García-AlbercaJM

Neurología 2015; 30: 8-15.

brain_languaje

Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: An ERP study.

2015

Barbancho MA, Berthier ML, Navas-Sánchez P, Dávila G, Green-Heredia C, García-Alberca JM, Ruiz-Cruces R, López-González MV, Dawid-Milner MS, Pulvermüller F, Lara JP

Brain Lang. 2015; 145-146:1-10.

geriatric_2015

Dependence Scale for Alzheimer’s Disease: Relationship With Other Clinical Indicators and Psychometric Properties

2015

Garre-Olmo J, Vilalta-Franch J, Calvó-Perxas L, Monserrat-Vila S, López-Pousa S, theCoDep-ADStudyGroup

Journal of Geriatric Psychiatry and Neurology 2015; 28:117-125.

jamda_16

Assessment of Long-term Cognitive Impairment After Off-pump Coronary-Artery Bypass. Grafting and Related Risk Factors

2015

Pérez-Belmonte LM, San Román-Terán CM, Jiménez-Navarro M, Barbancho MA, García-AlbercaJM,LaraJP

Journal of the American Medical Directors Association 2015; 16: 263-269.

A Path Analysis of Dependence and Quality of Life in Alzheimer's Disease

Neuropsychiatric Symptoms in Patients With Alzheimer’s Disease: The Role of Caregiver Burden and Coping Strategies.

2014

García-Alberca JM, Lara JP, Garrido V, Gris E, González-Herero V, Lara A.

American Journal of Alzheimer´s Disease and Other Dementias 2014; 29: 354-361.

nervous_mental_junio

Sleep disturbances in Alzheimer´s disease are associated with neuropsychiatric symptoms and antidementia treatment

2013

García-Alberca JM,  Lara JP, Cruz B, Garrido V, Gris E, Barbancho MA

Journal of Nervous and Mental Disease 2013; 201: 251- 257.

aging_mental_2013

The experience of caregiving: the influence of coping strategies on behavioral and psychological symptoms in patients with Alzheimer’s disease

2013

García-Alberca JM, Cruz B, Lara JP, Garrido V, Gris E, Lara A, González-Herero V

Aging and Mental Health 2013; 17: 615-622.

neurologia_2103

Deterioro cognitivo disejecutivo en pacientes con enfermedad coronaria: asociación con variables clínicas

2013

Lara Muñoz JP, Pérez-Belmonte E, Olalla Mercadé E, Gutiérrez de Loma J, Barbancho Fernández MA,García-Alberca JM, Laín JM, San Román CM

Neurología 2013; 28: 183.

pub-jad1

Disengagement coping partially mediates the relationship between caregiver burden and anxiety and depression in caregivers of people with Alzheimer’s disease. Results from the MÁLAGA-AD study

2012

García-Alberca JM, Cruz B, Lara JP, Garrido V, Gris E, Lara A

Journal of Affective Disorders 2012: 136: 848-856.

pub-sic1

Anxiety and depression are associated with coping strategies in caregivers of Alzheimer’s disease patients: results from the MÁLAGA-AD study

2012

García-Alberca JM, Cruz B, Lara JP, Garrido V, Lara V, Gris E

International Psychogeriatrics 2012; 24: 1325-1334.

Psychiatry in Medicine 2011

Anxiety and depression in caregivers are associated with patient and caregiver characteristics in Alzheimer´s disease

2011

García-Alberca JM, Lara JP, Berthier M.

International Journal of Psychiatry in Medicine 2011; 41: 57-69.

pub-arc1

Can impairment in memory, language and executive functions predict neuropsychiatric symptoms in Alzheimer’s disease (AD)? Findings from a cross-sectional study

2011

García-Alberca JM, Lara JP, Berthier ML, Cruz B, Barbancho MA, Green C, González-Barón S

Archives of Gerontology and Geriatrics 2011; 52: 264–269.

pub-cli1

ERP evidence of therapy-related reorganization of language of patients with post stroke chronic aphasia

2011

Lara JP, Barbancho MA, Berthier ML, Green C, Navas P, David.Milner MS, García-Alberca JM, Ruiz-Cruces R, Pulvermüller F, Dávila G, González-Barón S

Clinical Neurophysiology 2011; 122 (Supp 1) S214-S215.

pub-alh1

Perfil de síntomas psicológicos y conductuales en pacientes con enfermedad de Alzheimer y demencia vascular

2010

Lara Muñoz JP, García-Alberca JM, Berthier Torres ML

Alzheimer. Realidades e Investigación en Demencias 2010; 46:5-14.

Sintomatología neuropsiquiátrica y conductual en la enfermedad de Alzheimer. Revisión

2010

García-Alberca JM, Lara JP Muñoz, M Berthier Torres

Actas Españolas de Psiquiatría 2010; 38:212-222.

Caracterización de las alteraciones del sueño en pacientes con enfermedad de Alzheimer. Relación con tratamientos farmacológicos

2010

Lara JP, García-Alberca JM, Berthier M, Green C, Dawid-Milner MS, Dávila G, Pulvermüller F

Neurología 2010; 25: 10-11.

ERPs correlates of recovery from chronic post-stroke aphasia in patients treated with memantine and constraint-induced aphasia therapy

2009

Lara JP, Barbancho MA,  Berthier M,  Green C, Navas P, Dawid-Milner MS, Dávila G, García-Alberca JM, Pulvermüller F

European Journal of Neurology 2009; 16 (Suppl. 3): 335-624.

Normalización de potenciales relacionados con eventos tras el efecto beneficioso de la memantina en afásicos crónicos postictus

2009

Lara JP, Barbancho MA, Berthier ML, Green C, Navas P,Dawid-Milner MS, Dávila G, García-Alberca JM, Pulvermüller F, González-Baron S.

Revista de Neurología 200; 24: 621-621.

Prevalencia y comorbilidad de síntomas neuropsiquiátricos en la enfermedad de Alzheimery

2008

García-Alberca JM, Lara JP, González-Barón S, Barbancho MA, Porta D, Berthier M

Actas Españolas de Psiquiatría 2008; 36:265-270.

Perfil clínico de pacientes con enfermedad de Alzheimer atendidos en centros de día psicogeriátricos

2008

García-Alberca JM, Lara JP, González-Barón S, Barbancho MA, Porta D, Berthier M

Anales de Psiquiatría 2008; 24: 145-152.

Rivastigmina en la enfermedad de Alzheimer

2008

Berthier ML, Green C, García-Alberca JM, Lara JP

Medicina  Clinica Monografías (Barc) 2008; 9:16-19.

Perfil de síntomas psicológicos y conductuales en pacientes con enfermedad de Alzheimer y demencia vascular

2008

Lara JP, García-Alberca JM, Berthier ML, Barbancho MA,  González-Barón S

Neurología 2008; 23: 617-724

Evidencia neurofisiológica del efecto beneficioso de la memantina y terapia restringida del lenguaje en afásicos crónicos postictus; estudio doble ciego, aleatorizado y controlado con placebo

2008

Lara JP, Barbancho MA,  Berthier M, Green C, Navas P, Dawid-Milner MS, Dávila G, García-Alberca JM, González-Barón S

Neurología 2008; 23: 617-724.

Mecanismos funcionales de desinhibición cognitiva en la enfermedad de alzheimer: estudio de caso-control con RMN 3T, PET y potenciales evocados cognitivos

2008

Berthier M,  Green C, Boán J, Lara JP, Fernández L, Ruiz J A,   Barbancho MA,  Gómez J, Arbizu J, Dávila G, García-Alberca JM, Pulvermüller F

Neurología 2008; 23: 617-724.

Correlación entre el deterioro en memoria y funciones ejecutivas con los síntomas neuropsiquiátricos en pacientes con enfermedad de Alzheimer

2008

Lara JP, García-Alberca JM, González-Barón S, Berthier ML

Revista de Psiquiatría y Salud Mental 2008; 1: 93-93.

Demencia vascular: relación entre deterioro funcional y síntomas neuropsiquiátricos

2008

García-Alberca JM, Lara JP, Green C, González Barón S, Berthier M

Revista de Psiquiatría y Salud Mental 2008; 1: 93-94.

Relación entre la presencia de síntomas neuropsiquiátricos y la carga del cuidador en pacientes con enfermedad de Alzheimer

2008

García-Alberca JM, Lara JP, González Barón S, Berthier M

Revista de Psiquiatría y Salud Mental 2008; 1: 94-94.

Características sociodemográficas y clínicas de pacientes con enfermedad de Alzheimer y sus cuidadores principales

2008

García-Alberca JM, Lara P, González-Barón S, Berthier M

Málaga Científica 2008; 112: 32-37.

Influencia de los síntomas conductuales y psicológicos en la carga y sufrimiento del cuidador en un grupo de pacientes con enfermedad de Alzheimer

2007

García-Alberca JM, Lara JP, Porta D, González Barón S, Berthier M

Neurologia 2007, 22: 723-723.

Deterioro funcional y síntomas psicológicos y conductuales en un grupo de pacientes con demencia vascular

2007

García-Alberca JM, Lara JP, Green C, González Barón S, Berthier M

Neurología 2007, 22: 723-724.

Estudio en afásicos crónicos postictus del procesamiento del lenguaje mediante potenciales cognitivos relacionados con eventos

2007

Lara JP,  Barbancho MA, Montes C, Berthier M, Green C, Dawid-Milner MS, García-Alberca JM, Pulvermüller F, González-Barón S

Neurología 2007, 22: 724-724.

Correlaciones entre funciones ejecutivas y de memoria y síntomas conductuales y psicológicos en un grupo de pacientes con enfermedad de Alzheimer

2007

Lara JP, García-Alberca JM, Barbancho MA, González-Barón S, Berthier M

Neurología 2007; 22: 804-804.

Trastornos neuropsiquiátricos y función cognitiva en la enfermedad de Alzheimer

2006

García-Alberca JM, González Barón S, Berthier M, Lara JP

Psiquiatría Biológica 2006; 13 (Supl. 3): 78-78.

Perfil cognitivo y síntomas conductuales y psicológicos en un grupo de pacientes con enfermedad de Alzheimer

2006

Lara JP, García-Alberca JM, González Barón S, Berthier M

Neurología 2006; 21: 677-678.

Frecuencia y gravedad de los síntomas conductuales y psicológicos en la enfermedad de Alzheimer

2005

García-Alberca JM, Berthier M, González Barón S, Lara JP

Revista  de Neurología 2005; 41 (Supl 2): 55-95.

Prevalencia y evolución de los síntomas psicológicos y conductuales en la enfermedad de Alzheimer

2005

García-Alberca JM, González Barón S, Berthier M, Lara JP

Actas Españolas de Psiquiatría 2005, 33: 60-60.

Deterioro funcional y síntomas psicológicos y conductuales en un grupo de pacientes con enfermedad de Alzheimer

2005

Lara JP, García-Alberca JM, González Barón S, Berthier M

Neurología 2005; 20 (Supl 9): 513-514.

Cognitive–behavioural treatment for depression in Alzheimer’s disease patients: a case study

Cognitive–behavioural treatment for depression in Alzheimer’s disease patients: a case study

2016

García-Alberca JM

Psychogeriatrics 2017; 17:200-201.

(Click on the green buttons to navigate through the pages)